CXBS (Corix Bioscience) ROE % Adjusted to Book Value: -43.01% (As of Sep. 2017)


What is Corix Bioscience ROE % Adjusted to Book Value?

Corix Bioscience CXBS -99.00% ROE % Adjusted to Book Value is -43.01% as of Sep. 2017.

Corix Bioscience's ROE % for the quarter that ended in Sep. 2017 was -249.88%. Corix Bioscience's PB Ratio for the quarter that ended in Sep. 2017 was 5.81. Corix Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2017 was -43.01%.

Corix Bioscience ROE % Adjusted to Book Value Related Terms

Corix Bioscience ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience ROE % Adjusted to Book Value Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -92.48

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.98 -5.87 0.00 -45.05 -43.01

CXBS vs BKIT, YBAO, HSTI: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's ROE % Adjusted to Book Value falls into.


Corix Bioscience ROE % Adjusted to Book Value Calculation

Corix Bioscience's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2016 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-197.90% / 2.14
=-92.48%

Corix Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2017 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-249.88% / 5.81
=-43.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -43.01% mean?
Corix Bioscience (CXBS) has a ROE % Adjusted to Book Value of -43.01% as of Sep. 2017. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's ROE % Adjusted to Book Value too high?
Corix Bioscience's current ROE % Adjusted to Book Value is -43.01%.
How does Corix Bioscience's ROE % Adjusted to Book Value compare to BKIT and YBAO?
Corix Bioscience's ROE % Adjusted to Book Value of -43.01% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Corix Bioscience and its competitors. Corix Bioscience's current ROE % Adjusted to Book Value is -43.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current ROE % Adjusted to Book Value of -43.01%. The current ROE % Adjusted to Book Value is -43.01%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current ROE % Adjusted to Book Value is -43.01% as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.